This Dividend Stock's Secret Weapon?

When investors discuss pharmaceutical company AbbVie , the conversation tends to steer toward its key product, Humira, which reigns as both the company's biggest cash generator and the best-selling medication in the world. But arguably the biggest opportunities that AbbVie has going forward are the experimental drugs in its pipeline. What does this growing pharma have in clinical trials today?

In the following video, from The Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso shine the spotlight on AbbVie's pipeline and explain what investors need to watch.

9 solid dividend stocks
One of the best parts of owning Big Pharma stocks like AbbVie is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The article This Dividend Stock's Secret Weapon? originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D., owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.